2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - Hall C
This session surveys the latest early-phase clinical data shaping the treatment landscape for chronic myelomonocytic leukemia (CMML), higher-risk myelodysplastic syndromes (MDS), and MDS/MPN overlap disorders. Presentations span first-in-human results for a novel CCR2-targeting cytotoxicity chimera, combination regimens pairing hypomethylating agents with venetoclax and other cytotoxic or immune-targeting partners (anti-CD47, anti-IL1RAP), and an all-oral treatment approach for MDS/MPN overlap syndromes. A pediatric-focused study extends the discussion to secondary myeloid neoplasms. Together, these studies reflect the field's ongoing shift toward targeted and combination-based strategies aimed at improving outcomes across this heterogeneous group of hard-to-treat myeloid malignancies.
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Immunotherapy, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, MDS, MPN, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

529 CPX-351 is effective for remission induction for pediatric patients with secondary myeloid neoplasms.

Alyssa L. Kennedy, MD, PhD, Yonghui Ni2, Brittany Cowfer, MD3, Caitlyn Duffy, MD4, Saman Hashmi, MD5, Hiroto Inaba, MD. PHD6, Seth E. Karol, MD, MSCI7, Jeffery M. Klco, Member; Director, Division of Hematopathology and Molecular Pathology8, Amr Qudeimat, MD9, Matthew Rees, MD10, Stanley Pounds, PhD11, Raul Ribeiro, MD12, Marcin W Wlodarski, MD, PhD13
1 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
2 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
3 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
4 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
5 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
6 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
7 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
8 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
9 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
10 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
11 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
12 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
13 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States

Background: Secondary myeloid neoplasms (SMN) are extremely rare and heterogeneous disorders that may arise following cytotoxic therapy for a primary pediatric malignancy, in the context of a constitutional predisposition to leukemia, or through the combined effects of both conditions. CPX-351 (Vyxeos) has been approved for pediatric patients with treatment-related acute myeloid leukemia or AML with myelodysplasia-related changes based largely on efficacy data from adults and pharmacokinetic data from children and adolescents. However, prospective data regarding its efficacy and toxicity in a diverse, molecularly characterized pediatric SMN population remain limited. We therefore conducted a prospective, single-institution, phase II study of CPX-351 in patients younger than 21 years with SMN defined according to World Health Organization criteria (NCT05656248). All patients had an indication for systemic therapy before hematopoietic stem cell transplantation.

Methods: Patients received CPX-351 at 100 units/m² (cytarabine 100 mg/m² and daunorubicin 44 mg/m²) on days 1, 3, and 5 of cycle 1. Cycle 2 treatment was response-adapted. Patients who achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi) with measurable residual disease (MRD) <0.1% proceeded to HSCT or received reduced-dose CPX-351 (cytarabine 65 mg/m² and daunorubicin 29 mg/m²) if HSCT was delayed. Patients with persistent disease received standard-dose CPX-351. Response was assessed by bone marrow examination on day 22 of each cycle, with MRD evaluated by flow cytometry at a sensitivity of 0.1%. The primary efficacy endpoint was the composite CR/CRi rate, evaluated using a Simon two-stage minimax design (n=25; 80% power to distinguish a response rate of ≥70% from a null rate of 45%). Tolerability was evaluated using a three-stage design with 88.8% probability to declare the regimen tolerable if the true proportion of patients completing two cycles without grade 4–5 nonhematologic toxicity was 70%. Secondary endpoints included characterization of respiratory and cardiac toxicities, biological correlates of response, and 3-year overall and event-free survival following one or two cycles of CPX-351 and subsequent HSCT.

 Results: Twenty-five patients were enrolled at St. Jude Children’s Research Hospital between January 17, 2023 and July 24, 2025. Sixteen patients (64%) had treatment-related AML or MDS. The median age was 11.2 years (range, 4.2–19.2), and 16 patients (64%) were male. The molecular landscape was highly heterogeneous with multiple patients with KMT2A rearrangements (n=7), RUNX1 alterations or deletions of chromosome 7.
After one or two cycles of CPX-351, 20 of 25 patients achieved CR/CRi (80%; 95% CI, 59%–91%), significantly exceeding the prespecified null response rate of 45% (P=<0.001). Overall, this regimen was well tolerated. Among the 25 patients treated for up to two cycles to induce remission, only two unacceptable adverse events occurred, and the tolerability stopping rule was not met. There were no deaths attributed to therapy. Age, sex, and presenting diagnosis (MDS vs AML) were not associated with response. Disease etiology, however, influenced EFS: EFS in treatment-related SMN plateaued near 54%, whereas EFS in MDS/AML arising from germline predisposition fell to 0% by ~1.4 years (log rank p=0.043). Overall survival curves comparing treatment-related and germline-predisposed AML/MDS were similar (log-rank p = 0.061). All-cause mortality was 11/25 (44%).

Conclusions: CPX-351 produced a high CR/CRi rate with acceptable tolerability in children and adolescents with SMN. Underlying disease etiology, whether the patient had a germline cancer predisposition syndrome versus treatment related, emerged as a potentially important prognostic stratification variable. The steep early decline in survival among patients with germline predisposition-associated MDS/AML indicates that achieving remission with CPX-351 alone is insufficient to improve long-term outcomes in this subgroup. These findings highlight the need for optimized post remission therapy, including novel consolidation and maintenance strategies, for this particularly difficult-to-treat population. Molecular analyses are ongoing to identify mechanisms underlying the observed differences in treatment response, relapse, and survival.

Alyssa L. Kennedy, MD, PhD: No relevant conflicts of interest to declare.